Oxybutynin and Dementia Risk: Safer Bladder Options

Published on October 14, 2026 — by Ellen Bennett, Women’s Health Researcher

Medical & Affiliate Disclosure: This article is for educational purposes only and is not medical advice. Do not stop or change any prescription medication without talking to the doctor who prescribed it. Some links below are affiliate links for FemiCore; if you buy through them we may earn a commission at no extra cost to you. That does not change what we write.

Independent women’s health research · Written and fact-checked by Ellen Bennett, Women’s Health Researcher · Last verified: October 2026

Maybe you saw a headline about bladder pills and memory. Maybe your sister mentioned it, or a pharmacist hesitated for half a second when you picked up your refill. Now you are reading about oxybutynin and dementia at the kitchen table, wondering whether the pill that finally let you sleep through the night is doing something to your brain.

That worry deserves a straight answer, not a scary headline and not a brush-off. The short version: the concern is real, it is specific to one family of bladder drugs, it does not apply to every option, and there is a clear set of questions to bring to your doctor. Here is what the research shows, what the urology guidelines now say, and what your options are if you want to rely less on that family of drugs.

Why Oxybutynin Is Linked to Dementia

Oxybutynin belongs to a class called anticholinergic, or antimuscarinic, drugs. They work by blocking acetylcholine, a chemical messenger that tells the bladder muscle to squeeze. Block it, and the bladder relaxes and holds more, which is why these drugs reduce urgency and leaks.

The problem is that acetylcholine is also one of the brain’s main messengers for memory and attention. Some bladder antimuscarinics, oxybutynin in particular, cross from the bloodstream into the brain fairly easily. Short-term, that can show up as dry mouth, constipation, fogginess or confusion, especially in older adults. The long-term question is whether years of blocking acetylcholine adds to the risk of dementia. That is what the big studies have tried to answer. If dry mouth is already part of your life, as it is for many women with Sjögren’s, see how Sjögren’s affects the bladder before choosing a bladder drug.

Oxybutynin and Dementia: What the Research Shows

The 2019 study that started the conversation

A 2019 study in JAMA Internal Medicine compared 58,769 people with dementia against 225,574 matched controls in England, 63% of them women, average age 82. People with the heaviest use of strongly anticholinergic drugs over the previous decade had higher odds of dementia. For bladder antimuscarinics specifically, heavy use, more than about three years of daily doses, was associated with 65% higher odds (adjusted odds ratio 1.65).

The 2024 study that compared bladder drugs one by one

A 2024 study in BMJ Medicine went further. It compared 170,742 people aged 55 and older who developed dementia with 804,385 who did not, and looked at each bladder drug separately, counting use from 3 to 16 years before diagnosis to reduce the chance that early dementia itself was driving the prescriptions.

Bladder medication	Association with dementia (2024 BMJ Medicine)
Oxybutynin	Higher risk: about 28–31% higher odds with more than a year of use
Solifenacin (Vesicare)	Higher risk: 18–29% higher odds with longer use
Tolterodine (Detrol)	Higher risk: about 25–27% higher odds with longer use
Trospium, fesoterodine (Toviaz), darifenacin, flavoxate, propiverine	No significant increase found
Mirabegron (Myrbetriq), a non-anticholinergic	Results varied and may reflect earlier anticholinergic use

Across all bladder antimuscarinics, the overall association was 18% higher odds (1.16 for women, 1.22 for men). The authors concluded that oxybutynin, solifenacin and tolterodine were the most strongly associated with dementia, and that doctors should consider alternatives in older adults.

A 2026 study in older women only

Most of this research mixes men and women, so a 2026 study in the International Journal of Urology is especially relevant here. It followed 3,794 Japanese women aged 65 to 84 who started either an anticholinergic bladder drug or a beta-3 agonist and stayed on it for at least a year. Women on anticholinergics had a 49% higher risk of a recorded dementia diagnosis than women on beta-3 agonists (hazard ratio 1.49). Reassuringly, there was no difference in frailty or in needing more long-term care. I compare the two drug types directly in mirabegron vs oxybutynin.

What these numbers do and do not mean

These are observational studies. They show an association, not proof that the drug causes dementia, and the researchers themselves note that confounding cannot be fully ruled out. They are also relative numbers. If your baseline risk of dementia over a decade is low, a 20–30% relative increase is still a small absolute change. But the signal is consistent across countries, study designs and years, it is strongest for the drugs that enter the brain most easily, and it is strongest with longer use. That is enough for the major guidelines to act on it.

What the Guidelines Now Say

The 2024 AUA/SUFU overactive bladder guideline, the main US urology guideline, includes a statement written for exactly this situation. Statement 18 says: “Clinicians should discuss the potential risk for developing dementia and cognitive impairment with patients with OAB who are taking, or who are prescribed, antimuscarinic medications.”

The same guideline says clinicians should offer bladder training to all patients with overactive bladder (a strong recommendation, Grade A evidence) and should offer either antimuscarinics or beta-3 agonists as medication options. In other words, a non-anticholinergic drug is considered an equal first choice, not a last resort.

Separately, the 2023 American Geriatrics Society Beers Criteria, the standard list of medications that are often inappropriate for older adults, includes bladder antimuscarinics among the strongly anticholinergic drugs that people with dementia or cognitive impairment should avoid.

Your Options: From Least to Most Intensive

If you are worried, you have more choices than “keep taking it” or “put up with the leaks.” Here is how they line up.

Option	What it is	What to know
Bladder training	Gradually stretching the time between bathroom trips	Grade A, first-line in the AUA guideline; no side effects. My bladder training schedule walks you through it.
Fluid, caffeine and trigger changes	Timing fluids, cutting bladder irritants, managing triggers	Low cost, often underused. See caffeine and bladder leaks.
Pelvic floor training	Urge-suppression contractions plus strengthening	Helps urgency and mixed leaks, not just stress leaks
Beta-3 agonists	Mirabegron (Myrbetriq), vibegron (Gemtesa)	Relax the bladder through a different pathway; not anticholinergic. Can raise blood pressure; cost and insurance vary.
Other antimuscarinics	Trospium, fesoterodine, darifenacin	No significant dementia signal in the 2024 study; trospium enters the brain less readily. Still anticholinergic.
Office procedures	Bladder Botox, tibial nerve stimulation, sacral neuromodulation	For symptoms that do not respond to the above
Supplements	Ingredient-based support, such as Urox, pumpkin seed or FemiCore	Can support bladder health alongside the above; not a replacement for medical care

The Conversation to Have With Your Doctor

Bring these questions to your next appointment, or to a pharmacist, who is often the fastest person to ask:

1. Which bladder medication am I on, and is it one of the ones linked to dementia? Oxybutynin, solifenacin and tolterodine had the strongest association in the 2024 study.
2. How long have I been on it, and do I still need this dose? The risk signal grew with longer use.
3. What is my total anticholinergic load? Sleep aids with diphenhydramine, some older antidepressants and some allergy pills add to the same effect. My guide to medications that cause bladder leaks lists the common culprits.
4. Would a beta-3 agonist or trospium make sense for me? Ask about blood pressure and cost.
5. Can we add bladder training and check again in eight weeks? Some women find they need less medication once training takes hold, and your doctor can judge whether that applies to you.
6. If I change, how do I do it safely? Never stop on your own. Symptoms can rebound, and your doctor may want to taper or switch directly.

Important: if you or your family have noticed new confusion, memory slips or personality changes, tell your doctor promptly. That is worth checking in its own right, whatever medication you are on.

Where Supplements Fit, Honestly

Many women who read about this want something gentler, and supplements are where they look. I think they can play a supporting role, but only if you match the supplement to the cause of your urgency.

If your urgency is pure overactive bladder, with no infections, the ingredient with the best evidence is Urox, a blend that beat placebo for daytime and nighttime trips in a 2018 randomized trial of 150 adults. I cover it in Urox for bladder control, and pumpkin seed extract in pumpkin seed extract for bladder control.

If your urgency came with, or after, repeat UTIs, menopause or a round of antibiotics, the problem may involve the urinary and vaginal microbiome as much as the bladder muscle. That is where FemiCore fits. It combines cranberry standardized to 30% proanthocyanidins with five named Lactobacillus strains, including L. crispatus, in one daily capsule, aimed at the bladder lining and the protective bacteria that thin out after menopause. It does not block acetylcholine, so it does not add to your anticholinergic load. The finished formula has not been tested in its own trial, and it is not a substitute for prescription treatment, but for the woman whose urgency started with infections, it targets the right problem. My full FemiCore review lays out the evidence ingredient by ingredient.

Whichever route you take, tell your doctor and pharmacist about any supplement you add. Some FemiCore ingredients, such as berberine, can interact with medications, which I cover in FemiCore side effects.

How to Reduce Urgency Without Adding Anticholinergic Load

These are the steps I would start this week, whatever you and your doctor decide about medication:

• Keep a three-day bladder diary. Time, amount, urge level, leaks. It shows your doctor what is really happening and tells you whether changes are working.
• Use urge suppression. When a strong urge hits, stop, stand still, do five quick pelvic floor squeezes, breathe out slowly, and walk calmly once it passes. Rushing makes it worse.
• Spread fluids evenly and taper after dinner, without cutting total water too far. My guide on how much water to drink with an overactive bladder has the numbers.
• Swap the evening caffeine and alcohol, two of the most common urgency triggers.
• Work on trigger moments, such as the urge that hits as you unlock the front door. Key-in-the-door urgency responds well to a simple retraining routine.
• Address nighttime trips separately, because the causes are often different. See nocturia in women.

Key Takeaways

• The link between oxybutynin and dementia is real but specific. Oxybutynin, solifenacin and tolterodine had the strongest association with dementia in a 2024 study of 170,742 people with dementia.
• Risk grows with longer use and is a relative increase, roughly 18–31% in the 2024 study, not a certainty.
• Older women are affected too: a 2026 study of 3,794 women aged 65–84 found 49% higher dementia risk on anticholinergics than on beta-3 agonists.
• Guidelines have caught up. The 2024 AUA/SUFU guideline asks doctors to discuss dementia risk; beta-3 agonists are an equal first-choice medication.
• Bladder training is Grade A and side-effect free. Start it regardless of what you decide about medication.
• Never stop a prescription on your own. Bring the six questions above to your doctor or pharmacist.

Frequently Asked Questions

Does oxybutynin cause dementia?

Large observational studies link long-term oxybutynin use to a higher risk of dementia, but they show an association, not proof of cause. A 2024 study of 170,742 people with dementia found oxybutynin use for more than a year was associated with 28 to 31% higher odds. Talk to your doctor before making any change.

Which bladder medication is safest for memory?

Beta-3 agonists such as mirabegron and vibegron work through a non-anticholinergic pathway, and a 2026 study of older women found a lower dementia risk with them than with anticholinergics. Among antimuscarinics, trospium, fesoterodine and darifenacin showed no significant dementia association in a 2024 study. Your doctor can weigh these against your blood pressure, other medications and cost.

Should I stop taking oxybutynin?

Do not stop on your own. Ask your doctor whether you still need it, whether a beta-3 agonist or another option would suit you, and how to switch safely. The 2024 AUA/SUFU guideline specifically asks clinicians to discuss dementia risk with patients taking these drugs.

Is the dementia risk from bladder pills reversible?

The research does not answer that clearly. The association is strongest with long-term, high cumulative use, which is one reason guidelines encourage reviewing these medications regularly and considering alternatives in older adults.

What are natural alternatives to oxybutynin?

Bladder training has Grade A evidence and is recommended for all patients with overactive bladder. Fluid timing, cutting caffeine and urge-suppression techniques also help. Among supplements, Urox has a 2018 placebo-controlled trial for urgency, and FemiCore combines cranberry with Lactobacillus strains for women whose urgency is tied to recurrent UTIs or menopause. Supplements support, but do not replace, medical care.

Do other medications add to the same risk?

Yes. Many common drugs are anticholinergic, including diphenhydramine sleep aids, some older allergy pills, some antidepressants and some medications for Parkinson's disease. A pharmacist can review your total anticholinergic load.

The Bottom Line

The research on oxybutynin and dementia is not a reason to panic, and it is not a reason to stop your medication tomorrow. It is a reason to have a specific conversation. The strongest signal belongs to the bladder drugs that enter the brain most easily, it grows with years of use, and the main US urology guideline now asks doctors to raise it with you. Bladder training costs nothing and has the best evidence of all, beta-3 agonists are an equal first choice, and for women whose urgency is tied to infections or menopause, a microbiome-focused supplement such as FemiCore can support the plan without adding to your anticholinergic load.

— Ellen Bennett

Further reading: stress vs urge incontinence, the best bladder control supplements of 2026 and the complete guide to bladder leaks.